Avastin

Avastin

bevacizumab

Manufacturer:

Roche

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Bevacizumab
Indications/Uses
In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination w/ paclitaxel as 1st-line treatment of metastatic breast cancer (mBC). In addition to platinum-based chemotherapy as 1st-line treatment of unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). In combination w/ interferon α-2a as 1st-line treatment of advanced &/or metastatic renal cell cancer (mRCC). Glioblastoma w/ progressive disease following prior therapy as single agent. In combination w/ carboplatin & paclitaxel for front-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. In combination w/ carboplatin & gemcitabine for recurrent, platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior anti-VEGF treatment. In combination w/ paclitaxel, topotecan or pegylated liposomal doxorubicin in platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer patients who received no >2 prior chemotherapy regimens & who have not received prior anti-VEGF therapy. In combination w/ paclitaxel & cisplatin or paclitaxel & topotecan for persistent, recurrent or metastatic cervix carcinoma.
Dosage/Direction for Use
Metastatic colorectal cancer (mCRC) 5 or 10 mg/kg once every 2 wk, or 7.5 or 15 mg/kg once every 3 wk. mBC 10 mg/kg once every 2 wk or 15 mg/kg once every 3 wk. Advanced, metastatic or recurrent NSCLC Addition to cisplatin: 7.5 mg/kg once every 3 wk. Addition to carboplatin: 15 mg/kg once every 3 wk. Advanced &/or mRCC & glioblastoma 10 mg/kg once every 2 wk. Epithelial ovarian, fallopian tube & primary peritoneal cancer Front-line: 15 mg/kg once every 3 wk in addition to carboplatin & paclitaxel for up to 6 cycles followed by continued use as single agent until disease progression. Recurrent platinum-sensitive: 15 mg/kg once every 3 wk in combination w/ carboplatin & paclitaxel for 6 cycles & up to 8 cycles followed by continued use as single agent until disease progression. Alternatively, 15 mg/kg once every 3 wk in combination w/ carboplatin & gemcitabine for 6 cycles & up to 10 cycles followed by continued use as single agent until disease progression. Recurrent platinum-resistant: 10 mg/kg once every 2 wk in combination w/ paclitaxel, topotecan (given wkly) or pegylated liposomal doxorubicin. Alternatively, 15 mg/kg every 3 wk in combination w/ topotecan given on days 1-5, every 3 wk. Cervical cancer 15 mg/kg once every 3 wk.
Contraindications
Hypersensitivity to Chinese hamster ovary cell products or recombinant human or humanised Ab.
Special Precautions
Hypersensitivity & infusion reactions. GI perforations, fistulae & non-GI fistulae formation. Hemorrhage. Severe eye infections following compounding for unapproved intravitreal use. Pulmonary hemorrhage/hemoptysis. HTN. Posterior reversible encephalopathy syndrome. Arterial & venous thromboembolism. CHF. Neutropenia. Wound healing, necrotising fasciitis secondary to wound healing complications. Proteinuria. May affect ability to drive & use machines. Renal & hepatic impairment. May impair female fertility. Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Not to be used in childn <18 yr.
Adverse Reactions
Febrile neutropenia, leucopenia, neutropenia, thrombocytopenia; anorexia, hypomagnesaemia, hyponatraemia; peripheral sensory neuropathy, dysgeusia, headache, dysarthria; eye disorder, increased lacrimation; HTN; dyspnoea, epistaxis, rhinitis, cough; diarrhoea, nausea, vomiting, abdominal pain, constipation, stomatitis, rectal haemorrhage; ovarian failure; exfoliative dermatitis, dry skin, skin discolouration; arthralgia; proteinuria; asthenia, fatigue, pyrexia, pain, mucosal inflammation; decreased wt. Sepsis, abscess, cellulitis, infection; anaemia, lymphopenia; dehydration; CVA, syncope, somnolence; congestive cardiac failure, supraventricular tachycardia; arterial thromboembolism, DVT, haemorrhage; pulmonary embolism, hypoxia; intestinal perforation & obstruction, ileus, recto-vag fistulae, proctalgia; palmar-plantar erythrodysaesthesia syndrome; muscular weakness, myalgia, back pain; UTI; lethargy; pelvic pain.
Drug Interactions
Microangiopathic haemolytic anaemia w/ sunitinib malate.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC07 - bevacizumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Avastin infusion 100 mg/4 mL
Packing/Price
1's
Form
Avastin infusion 400 mg/16 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in